Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Psoriasis

Psoriasis Medicines in India: Imported Biologics and Tablets for Skin and Joints

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERPsoriasis is a long-term immune disease that speeds up skin-cell turnover and leaves thick, scaly plaques. Hospital studies in India put it at 0.44% to 2.8% of patients seen, and men are affected about twice as often as women [1]. Mild disease is usually managed with creams, light therapy or older tablets. When plaques cover a large area, keep returning, or the joints become involved (psoriatic arthritis), dermatologists may consider newer biologic injections or targeted tablets approved in the US or China that Indian chemists do not usually stock. At present NPP (Named Patient Program) can source 11 of them, each brought in for a single named patient once a dermatologist or rheumatologist has prescribed it.
0.44–2.8%
is how common psoriasis is in India by mostly hospital-based studies; it most often affects people in their third or fourth decade of life
Source: Indian Journal of Medical Research, 2017 [1]
2 : 1
men to women with psoriasis in India, according to the same national review
Source: Indian Journal of Medical Research, 2017 [1]
8.7%
of 1,149 psoriasis patients screened at PGIMER Chandigarh had psoriatic arthritis (100 people), and 83 of those 100 learnt about it only through the screening
Source: PGIMER study, IJDVL 2014 [2]
44.1%
of 118 adults with psoriasis in Chennai had metabolic syndrome, compared with 30% of 120 matched people without psoriasis
Source: Sri Ramachandra hospital study [3]

Plaque, pustular and joint disease: which form is it?

Psoriasis is driven by an overactive immune signal, not by an infection, so it cannot pass from one person to another. The same disease can show up in quite different ways, and the form decides which medicines are approved.

FormWhat you seeApproved medicines on this page
Plaque psoriasis (psoriasis vulgaris)Raised red or dark patches with silvery scale, often on elbows, knees, scalp and lower backAll nine plaque psoriasis medicines here are for moderate-to-severe disease in people who need whole-body treatment or light therapy
Psoriatic arthritis (PsA)Painful, swollen joints, a whole finger or toe swollen like a sausage (dactylitis), heel or tendon pain, nail pittingBimzelx, Skyrizi, Sotyktu, Humira, Rinvoq and Orencia
Generalized pustular psoriasis (GPP)Sudden widespread pus-filled spots on red skin, often with fever; needs hospital careNone of the medicines below is approved for GPP itself; treatment is decided by the hospital team
Scalp, nail, palm and sole psoriasisPlaques in small but hard-to-treat placesUsually a pattern of plaque psoriasis; your dermatologist judges whether the overall disease is moderate to severe

GPP is rare but not unknown in India. At PGIMER Chandigarh, 46 of 857 new psoriasis patients seen between March 2022 and March 2025 had the pustular form, about 5.3% [4].

What Indian research tells us about psoriasis

Large population surveys of psoriasis have not been done in India; the numbers we have come from hospital clinics [1]. Worldwide the picture is similar: a 2020 BMJ analysis found that 81% of countries have no data on how common psoriasis is [6]. Even so, Indian studies point to three things a patient should know.

  • Joint damage is often missed. In the Chandigarh screening study, most people found to have psoriatic arthritis had not been told about it before [2]. Morning stiffness, a swollen finger or heel pain deserve a mention to your dermatologist.
  • Heart and sugar risks travel with psoriasis. The Chennai study saw more metabolic syndrome, high triglycerides and raised blood sugar in people with psoriasis than in matched controls, and found no link between how severe the skin disease was and metabolic syndrome [3]. Regular checks of weight, sugar, lipids and blood pressure are part of good care.
  • Tuberculosis screening matters more here. India carries one of the largest TB burdens in the world, estimated at 2.79 million cases in 2016 [5]. Many psoriasis medicines lower immune defences, so latent TB is looked for before they are started.

Imported psoriasis medicines by type

All 11 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Bimzelx (bimekizumab)
Bimzelx
bimekizumab · Subcutaneous pen
Adults whose plaque psoriasis is moderate to severe and needs systemic or light treatment; also adults with active psoriatic arthritis
Plaque psoriasisPsoriatic arthritis US FDA
Skyrizi (risankizumab)
Skyrizi
risankizumab · Subcutaneous pen
Age 6 and above: moderate-to-severe plaque psoriasis needing systemic or light treatment, and active psoriatic arthritis (also approved for Crohn's disease and ulcerative colitis)
Plaque psoriasisPsoriatic arthritis US FDA
Sotyktu (deucravacitinib)
Sotyktu
deucravacitinib · Tablet
Adults with moderate-to-severe plaque psoriasis needing systemic or light treatment; psoriatic arthritis in adults was added to the US label (July 2026)
Plaque psoriasisPsoriatic arthritis US FDA
Humira (adalimumab)
Humira
adalimumab · Subcutaneous pen / syringe
Adults with moderate to severe chronic plaque psoriasis when other systemic options are medically less suitable; adults with active psoriatic arthritis
Plaque psoriasisPsoriatic arthritis US FDA
Rinvoq (upadacitinib)
Rinvoq
upadacitinib · Tablet
Active psoriatic arthritis, age 2 and above, when at least one TNF blocker has not worked well enough or caused side effects
Psoriatic arthritis US FDA
Orencia (abatacept)
Orencia
abatacept · IV infusion / subcutaneous syringe
Active psoriatic arthritis in patients aged 2 years and above
Psoriatic arthritis US FDA
Vunakizumab (vunakizumab)
Vunakizumab
vunakizumab · Subcutaneous pen / syringe
IL-17A antibody in adults whose plaque psoriasis is moderate to severe and needs systemic or light treatment; NMPA approval August 2024
Plaque psoriasis China NMPA
Xeligekimab (xeligekimab)
Xeligekimab
xeligekimab · Subcutaneous syringe
IL-17A antibody (Jinlixi) in adults whose plaque psoriasis is moderate to severe and needs systemic or light treatment; NMPA approval August 2024
Plaque psoriasis China NMPA
Ebdarokimab (ebdarokimab)
Ebdarokimab
ebdarokimab · Subcutaneous syringe
IL-12/23 (p40) antibody in adults whose plaque psoriasis is moderate to severe, used after other systemic treatment or PUVA failed or was unsuitable; NMPA approval April 2025
Plaque psoriasis China NMPA
Picankibart (picankibart)
Picankibart
picankibart · Subcutaneous pen
IL-23 antibody in adults whose plaque psoriasis is moderate to severe and needs whole-body treatment; NMPA approval November 2025
Plaque psoriasis China NMPA
Amdokitug (amdokitug)
Amdokitug
amdokitug · Subcutaneous injection
IL-17A antibody in adults whose plaque psoriasis is moderate to severe and needs systemic or light treatment; NMPA approval February 2026
Plaque psoriasis China NMPA

Compare all 11 psoriasis medicines

MedicineGeneric namePsoriasis typeFormApproved by
BimzelxbimekizumabPlaque psoriasis, Psoriatic arthritisSubcutaneous penUS FDA
SkyrizirisankizumabPlaque psoriasis, Psoriatic arthritisSubcutaneous penUS FDA
SotyktudeucravacitinibPlaque psoriasis, Psoriatic arthritisTabletUS FDA
HumiraadalimumabPlaque psoriasis, Psoriatic arthritisSubcutaneous pen / syringeUS FDA
RinvoqupadacitinibPsoriatic arthritisTabletUS FDA
OrenciaabataceptPsoriatic arthritisIV infusion / subcutaneous syringeUS FDA
VunakizumabvunakizumabPlaque psoriasisSubcutaneous pen / syringeChina NMPA
XeligekimabxeligekimabPlaque psoriasisSubcutaneous syringeChina NMPA
EbdarokimabebdarokimabPlaque psoriasisSubcutaneous syringeChina NMPA
PicankibartpicankibartPlaque psoriasisSubcutaneous penChina NMPA
AmdokitugamdokitugPlaque psoriasisSubcutaneous injectionChina NMPA

How these psoriasis medicines differ from one another

All of them calm a specific immune messenger, but they differ in target, form and how often they are taken. Your dermatologist or rheumatologist weighs these against your other illnesses, earlier treatment and pregnancy plans.

GroupMedicines hereHow it is taken (as per the label or our drug page)
IL-17 blockersBimzelx (IL-17A and IL-17F), Vunakizumab, Xeligekimab, AmdokitugInjection under the skin; for plaque psoriasis, Bimzelx 320 mg is given five times four weeks apart (weeks 0 to 16) and then once in eight weeks
IL-23 blockersSkyrizi, PicankibartInjection under the skin; adult Skyrizi dosing is 150 mg at the start, again four weeks later, and after that once in 12 weeks
IL-12/23 blockerEbdarokimabInjection under the skin; after two starting doses, once every 12 weeks
TYK2 inhibitorSotyktuOne 6 mg tablet a day, with or without food
TNF blockerHumiraInjection under the skin; for plaque psoriasis it is meant for when other whole-body treatments are less suitable
JAK inhibitorRinvoqTablet once a day; for psoriatic arthritis after one or more TNF blockers did not work or were not tolerated
T-cell co-stimulation modulatorOrenciaDrip in hospital or injection under the skin; for psoriatic arthritis only

Tests usually done before the first dose

  • TB check: the US labels of Bimzelx, Humira, Rinvoq and Sotyktu ask doctors to look for TB infection before treatment; for Skyrizi the label leaves it to clinical judgement.
  • Infection and hepatitis checks: Humira and Rinvoq carry a boxed warning about serious infections, and the Humira, Rinvoq and Orencia labels all discuss hepatitis B, so your doctor may order hepatitis and blood tests first.
  • Severity record: a PASI score or body-surface-area note from your dermatologist, and for joint disease, a rheumatologist's assessment, show that the approval criteria are met.
  • Vaccines: the US labels of all six US-approved medicines here say to avoid live vaccines during treatment, so ask about any pending vaccination before starting.

Import permission, cold-chain delivery and paying for long treatment

Because these medicines are not on Indian pharmacy shelves, each pack is imported against one patient's name. Form 12A goes to CDSCO in the patient's own name after our pharmacist has drafted it, the import is then allowed through a Form 12B permit, and the rule behind this is set out on our Indian import regulations page; the documents needed are listed on our Form 12A and 12B guide. Bimzelx, Skyrizi, Humira and Orencia must be kept at 2–8 °C according to their US labels, so packs travel in a monitored cold box to the hospital pharmacy named in the permit, as explained on our hospital delivery page.

Psoriasis treatment with a biologic or tablet usually continues for months or years. Company programs, government schemes and charities that may ease the long-term cost are explained where we cover help with treatment costs.

How to get these psoriasis medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about psoriasis

References

  1. Thappa DM, Munisamy M. Research on psoriasis in India: where do we stand? Indian J Med Res. 2017;146(2):147-149. https://pubmed.ncbi.nlm.nih.gov/29265013/
  2. Kumar R, Sharma A, Dogra S. Prevalence and clinical patterns of psoriatic arthritis in Indian patients with psoriasis. Indian J Dermatol Venereol Leprol. 2014;80(1):15-23. https://pubmed.ncbi.nlm.nih.gov/24448118/
  3. Madanagobalane S, Anandan S. Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris: a hospital-based case-control study. Indian J Dermatol. 2012;57(5):353-7. https://pubmed.ncbi.nlm.nih.gov/23112353/
  4. Dogra S et al. Epidemiology, disease characteristics and treatment outcomes of generalized pustular psoriasis in India. Clin Exp Dermatol. 2026;51(4):571-577. https://pubmed.ncbi.nlm.nih.gov/41229319/
  5. Sarkar S et al. Risk of tuberculosis with anti-TNF-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population. Indian J Dermatol Venereol Leprol. 2020;86(1):1-7. https://pubmed.ncbi.nlm.nih.gov/31719235/
  6. Parisi R et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://pubmed.ncbi.nlm.nih.gov/32467098/
  7. US FDA prescribing information for each US-approved medicine (DailyMed). https://dailymed.nlm.nih.gov/dailymed/

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Psoriasis Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP